Apixaban for treatment of venous thromboembolism (VTEtx): Use of MBMA to support Phase 3 dose selection and beyond
Apixaban is an orally available, direct, selective inhibitor of the coagulation factor Xa that reversibly…
Certara2018 年 6 月 2 日
Pharmacokinetic/ Toxicokinetic Services
As your partner for drug development and regulatory strategy, Certara has expanded its services to…
Certara2018 年 5 月 18 日
What’s New in Enterprise 3.4 Q&A
Is there documented guidance on the creation of the sponsor SDTM metadata to be uploaded…
Certara2018 年 5 月 17 日
Achieving Compliance with the FDA’s eCTD Mandate
The US Food and Drug Administration (FDA) has set 2018 年 5 月 5 日 as the compliance…
Certara2018 年 5 月 4 日
